Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 28, 2022; 28(24): 2654-2666
Published online Jun 28, 2022. doi: 10.3748/wjg.v28.i24.2654
Published online Jun 28, 2022. doi: 10.3748/wjg.v28.i24.2654
Table 1 Studies comparing drug-induced autoimmune hepatitis and drug-induced liver injury
Ref. | a: Study population; b: Study period; c: Follow-up period | a: Definition of DIAIH; b: Causality tool assessment | No. of DIAIH cases, % of all DILI | No. of DILI cases | Key findings for DIAIH (in addition to Table 3) |
Stephens et al[37], 2021, Spain | a: Prospective multicentre DILI database, n = 869; b: 1994-2018; c: Median 96-117 d in HC injury | a: Simplified AIH criteria; b: RUCAM (definite, highly probable, probable and possible) | 26, 2.9% | 843 | Culprit drugs: Statins (31%); antimicrobials (23%) |
De Boer et al[15], 2015, United States | a: National prospective DILI database (n = 1322), subgroup of DILI secondary to Nitrofurantoin, hydralazine, Minocycline and methyldopa (n = 88); b: 2004-2014; c: 6 mo, 12 mo or 24 mo until normalization of LFT | a: Autoimmune (AI) DILI–AI score based on seropositivity for AIH antibodies and raised IgG); b: RUCAM (definite, highly probable and probable) | 47, 3.6% | Two groups: (a) 18 non-AI DILI due to 4 drugs; (b) 67 (reference cohort, DILI due to Augmentin, Isoniazid, Diclofenac) | Similar HLA-DRB1*03:01 (15%) and HLADRB1*04:01 (9%) percentage in patients with DILI compared to population controls from National Marrow Donor Program (12% and 9%, respectively) |
Hisamochi et al[22], 2016, Japan | a: All DILI who underwent liver biopsy, n = 62; b: 1988-2010; c: Median 2290 d | a: Revised IAIHG criteria; b: RUCAM and JDD-W scale | 23, NA | 39 | Culprit drugs: CAM (69.6%); NSAIDs (8.7%). IgG reduction in 87%. 50% (8/16) relapsed (4 not treated with steroids, 2 previously received steroids and 2 on tapering dose of steroid dosage). Median time to relapse 283 d (range, 47-1090 d). Rise in IgG with relapse |
Licata et al[16], 2014, Italy | a: Single centre hospitalized patients with DILI, n =136 (44 with liver biopsy); b: 2000-2011; c: Mean 26 mo (12-84 mo), at least 1 yr after stopping immunosuppressants | a: Simplified AIH score ≥ 6; b: RUCAM (definite, highly probable, probable and possible) | 12, 8.8% | 124 | Culprit drugs: NSAIDs (50%) - (Nimesulide/ketoprofen); Antimicrobials (25%) (Augmentin/Ceftriaxone); CAM (17%). 38.2% of all DILI patients had positive AIH antibodies but only 42.9% with positive antibodies have DIAIH. All DIAIH were treated with corticosteroids and all achieved remission at 15 mo. 58.3% (7/12) had addition of Azathioprine. One patient had a flare while on tapering prednisolone. In 41% (5/12), immunosuppressant was stopped after 2 yr, with no relapse |
Table 2 Studies comparing drug-induced autoimmune hepatitis and autoimmune hepatitis
Ref. | a: Study population; b: Study period; c: Follow-up period | a: Definition of DIAIH/AIH; b: Causality tool assessment | No. of DIAIH cases, % of all AIH | No. of AIH cases | Key findings for DIAIH (in addition to Table 4) |
Valgeirsson et al[14], 2019, Iceland | a: Population based AIH study, n = 71; b: 2006-2018; c: Median 4.8 yr | a: Simplified AIH score, if not fulfilled, Revised IAIHG score is used; or received corticosteroids; b: RUCAM score (highly probable, probable and possible) | 13, 18% (9/13 had liver biopsy) | 58 | Culprit drugs: Biologics (77%) - 80% were due to infliximab; Nitrofurantoin (15%) |
Martínez-Casas et al[34], 2018, Columbia | a: Single centre retrospective review of AIH cases, n = 190; b: 2010-2016; c: Mean 47.4 mo | a: Simplified AIH score; b: RUCAM | 12, 6.3% | 178 | Culprit drugs: Nitrofurantoin (67%); NSAIDs (17%) |
Wang et al[20], 2017, China | a: Single centre retrospective review of AIH and DILI patients; b: 2010-2014; c: NA | a: DILI with positive antibody; simplified AIH score; b: NA (DILI due to drugs/CAM within 6 mo of hospitalization) | 18 (12.4% of all DILI with positive antibody) | 52 | Culprit drugs: CAM, NSAIDs and antibiotics (no breakdown) |
Yeong et al[32], 2016, United Kingdom | a: Single centre retrospective AIH cases, n = 82; b: 2005-2013; c: Median 86.3 mo (14.6% < 18 mo) | a: Revised IAIHG criteria; b: RUCAM (highly probable, probable) | 11, 13.4% | 71 | Culprit drugs: Nitrofurantoin (36.4%); Statins (36.4%); CAM (18%) |
Weber et al[21], 2019, Germany | a: Single centre cohort of 288 acute liver injury patients who received corticosteroid for DILI/AIH, n = 44; b: 2013-2018; c: Median 19 mo in DILI; 23 mo in AIH | a: Simplified AIH score and revised IAIHG criteria; b: RUCAM | 22 | 22 | Culprit drugs: NSAIDs (27.3%); Statins (9%); Direct oral anticoagulants (9%) |
Björnsson et al[13], 2010, United States | a: Single centre retrospective review of all AIH cases, n = 261; b: 1997-2007 | a: Simplified AIH score | 24, 9.2% (24/261) | 237 | Culprit drugs: Minocycline (45.8%); Nitrofurantoin (45.8%) |
Table 3 Comparison between drug-induced autoimmune hepatitis and drug-induced liver injury
Clinical features | DIAIH | DILI |
Demographics | ||
Female, % | 62%[37] | 48% (P = 0.162)[37] |
Age (yr), mean ± SD | 57± 17[37]; 59 ± 17[22] | 54 ± 18 (P = 0.550)[37]; 47 (P = 0.002)[22] |
Clinical presentation | ||
Jaundice, % | 69%[37]; 68%[15]; 66%[16] | 69% (P = 0.953)[37]; 56% (P = 0.4)[15]; 40%-47.6% (P = 0.2)[16] |
Rash, % | 4.5%[37]; 19%[15] | 7.9% (P = 1.000)[37]; 22% (P = 0.7)[15] |
Hepatocellular injury, % | 92%[37] | 57% (P = 0.002)[37] |
Latency period (d), median (range) | 65 (27-274)[37]; 277 (8-7032)[15]; 4 (1-9)[16] | 27 (8-64) (P = 0.004)[37]; 100 (13-1572) (P = 0.03)[15]; 7-10 (5-50) (P = 0.7)[16] |
Latency period (d), mean ± SD | 143 ± 188[22] | 32 ± 120 (P = 0.000)[22] |
Culprit drug due to CAM, % | 70%[22] | 25% (P = 0.000)[22] |
Biochemical results | ||
ALT × ULN, mean ± SD | 28 ± 19[37] | 19 ± 22 (P = 0.0002)[37] |
AST × ULN, mean ± SD | 24 ± 17[37] | 15 ± 21 (P = 0.0001)[37] |
Autoimmune antibodies and serology | ||
Detectable ANA, % | 88%[37]; 72%[15]; 52%[22] | 12 (P < 0.001)[37]; 22[15]; 15 (P = 0.003)[22] |
Detectable ASMA, % | 44%[37]; 60%[15] | 8.9% (P < 0.001)[37]; 13%[15] |
Detectable AMA, % | 4%[37] | 1.9% (P = 0.397)[37] |
Detectable anti-LKM-1, % | 0%[37] | 1.1% (P = 1.000)[37] |
Elevated IgG, % | 39%[15]; (25% > 1.1 × ULN)[15] | 9%[15] |
Serum IgG (g/L), mean ± SD | 19.5 ± 10.7[37]; 1.07 × ULN ± 0.51[22] | 11.9 ± 4.6 (P < 0.001)[37]; 0.69 × ULN ± 0.28 (P = 0.000)[22] |
Histopathology | ||
Liver biopsy[16] | ||
Severe portal inflammation, % | 100% | 56.2%-62.5% |
Prominent portal plasma cells, % | 58.3% | 6.3%-12.5% |
Rosette formation, % | 66.7% | 6.3%-12.5% |
Severe focal necrosis, % | 66% | 6.3%-25% |
Treatment and response to treatment | ||
Corticosteroid therapy, % | 43%[15] | 61% (P = 0.3)[15] |
Immunosuppressive therapy, (corticosteroid/Azathioprine), % | 58%[37]; 60.8%[22] | 9.9% (P < 0.001)[37]; 10.3% (P = 0.000)[22] |
Outcomes | ||
Mild/mod/severe DILI, % | 35%/45%/7.7%[37] | 31%/59%/6.2% (P = 0.784)1[37] |
Outcomes (liver transplant/death), % | 3.8%/0%[37]; 6%/4%[15] | 2.1%/1.5% (P = 0.784)1[37]; 0/0 (P = 0.6 for liver transplant, P = 1.0 for death)[15] |
Chronicity rate, % | 17%[15] | 21% (P = 0.70)[15] |
Table 4 Comparison between drug-induced autoimmune hepatitis and autoimmune hepatitis
Clinical features | DIAIH | AIH |
Demographics | ||
Female, % | 82%[32]; 91%[34] | 80% (P = 0.635)[32]; 92% (P = 0.95)[34] |
Clinical presentation | ||
Acute presentation | > 60%[14]; 55%[32]; 83%[34] | < 20%[14]; 47% (P = 0.618)[32]; 35% (P < 0.001)[34] |
Hypersensitivity reaction (fever, rash, eosinophilia) | Up to 30%[14] | Unusual[14] |
Cirrhosis at presentation, % | 0%[34] | 34.8% (P = 0.07)[34] |
Temporal relationship with drugs | Positive | Negative |
Concurrent AI disease | Unusual[14] | Present in 14%-44%[14] |
Biochemical results | ||
ALT (U/L), mean ± SD | 548 ± 335[20] | 227 ± 121 (P = 0.021)[20] |
AST (U/L), mean ± SD | 460 ± 321[20] | 202 ± 57 (P = 0.018)[20] |
Serology | ||
IgG, mean ± SD (g/L) | 13.4 g/L[14]; 21.4 ± 7.5[34] | 18.6 g/L (P value non-significant)[14]; 24.3 ± 11.2 (P = 0.422)[34] |
Pre-treatment score | ||
RUCAM score, median (range) | 6 (3-10)[21] | 3.5 (0-7) (P < 0.01)[21] |
Revised IAIHG score, median (range) | 9.5 (4-14)[21] | 13 (9-18)[21] |
Simplified AIH score, median (range) | 4 (2-6)[21] | 5 (1-7) (P = 0.385)[21] |
Histopathology | ||
F3-F4, % | 33.3%[34] | 54.4% (P = 0.15)[34] |
Typical histology (portal inflammation, interface hepatitis, plasma cells infiltrates) | 18.2%[20] | 54%[20] |
Treatment and response to treatment | ||
Time to biochemical remission, mean (mo) | 2[34] | 16.8 (P <0.001)[34] |
Treatment with Azathioprine or Mycophenolic acid in addition to corticosteroids, % | 57%[13]; 15%[14]; 28%[20]; 20%[21] | 86% (P = 0.024)[13]; 83% (P < 0.001)[14]; 90% (P = 0.023)[20]; 85% (P < 0.01)[21] |
Biochemical remission, % | 95%[21] | 77.3% (P = 0.08)[21] |
Treatment discontinuation, % | 69%[14]; 100%[20]; 85%[21]; 25%[34] | 26% (P < 0.02)[14]; 25% (P = 0.013)[20]; 5% (P < 0.1)[21]; 3% (P < 0.001)[34] |
Relapse rate, % | 0%[14]; 15%[21]; 60%[32]; 0%[34] | 43% (P = 0.022)[14]; 70% (P < 0.01)[21]; 83% (P = 0.538)[32]; 18% (P = 0.10)[34] |
Time to relapse (wk), median (range) | 131 (37-216)[34] | 14 (1-155) (P = 0.033)[34] |
Outcomes | ||
Liver transplant/death, % | 0%/0%[32,34] | 2.8%/7% (P = 0.748 for liver transplant; p = 0.65 for death)[32]; 5.6%/2.8% (P = 0.40 for liver transplant; P = 0.55 for death)[34] |
- Citation: Tan CK, Ho D, Wang LM, Kumar R. Drug-induced autoimmune hepatitis: A minireview. World J Gastroenterol 2022; 28(24): 2654-2666
- URL: https://www.wjgnet.com/1007-9327/full/v28/i24/2654.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i24.2654